New FDA-approved test can ID leukemia patients for Revuforj
The U.S. Food and Drug Administration has approved a new rapid diagnostic test to identify patients with treatment-resistant acute leukemias who may benefit from the…
Blood cancer
Project aims to improve AML patients’ access to clinical trials
A new research project aims to make it easier for people with acute myeloid leukemia (AML) to participate in clinical trials. The project is led…
Cancer network backs Syndax Revuforj for NPM1-mutated AML
The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 33 cancer centers, included Revuforj (revumenib) in its clinical practice guidelines for treatment of relapsed or…
NASCAR car makeover driving awareness of pediatric blood cancer
The advocacy organization Blood Cancer United has teamed up with motor oil company Valvoline Global and auto racing group Hendrick Motorsports to raise awareness…
Cell therapy CER-1236 put on FDA fast track as AML treatment
The U.S. Food and Drug Administration (FDA) has granted fast track designation to CER-1236, an experimental cell therapy that Cero Therapeutics is developing to…
Xspray seeking FDA approval for oral CML treatment XS003
Xspray Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for its oral therapy XS003 (nilotinib) for the…
Blood cancer therapy SGR-2921 discontinued after patient deaths
Biotech company Schrödinger said it’s discontinuing the development of SGR-2921, an experimental therapy for certain types of blood cancer, following the deaths of…
FDA fast tracks birelentinib for certain hard-to-treat blood cancers
The U.S. Food and Drug Administration (FDA) granted fast track designation to birelentinib as a potential treatment for certain forms of blood cancer. The…
Scemblix now OK’d in Canada for treating newly diagnosed CML
More people in Canada with the rare blood cancer Ph+ CML — fully, Philadelphia chromosome-positive chronic myeloid leukemia — in the…
Aucatzyl approved in Europe for relapsed/refractory B-ALL
The European Commission has approved Autolus Therapeutics’ cell therapy Aucatzyl (obecabtagene autoleucel) as a treatment for B-cell precursor acute lymphoblastic leukemia (B-ALL), an aggressive…
